Home
Resources
Publications
Anti-gal A/B, a Novel Anti-Blood Group Antibody Identified in Recipients of Abo-Incompatible Kidney Allografts

Anti-gal A/B, a Novel Anti-Blood Group Antibody Identified in Recipients of Abo-Incompatible Kidney Allografts

Uri Galili, Hideki Ishida, Kazunari Tanabe, Hiroshi Toma

Transplantation. 2002 Dec 15;74(11):1574-80.

PMID: 12490791

Abstract:

Background:
The most prevalent anticarbohydrate antibodies in human serum are anti-Gal interacting specifically with the alpha-gal epitope (Galalpha1-3Galbeta1-4GlcNAc-R) and anti-blood group antibodies interacting with blood group A and B antigens. The alpha-gal epitope, although absent in humans, comprises part of the core of carbohydrate chain in A and B antigens. Therefore, it was of interest to determine whether immunoglobulin (Ig) G antibodies, elicited in patients rejecting ABO-incompatible kidney allografts, can interact with the alpha-gal epitope.
Methods:
Anti-A and anti-B antibodies were determined by enzyme-linked immunosorbent assay (ELISA) with blood group A or B human red cell membranes, as solid phase antigens. Anti-Gal was determined by ELISA with alpha-gal-bovine serum albumin as solid-phase antigen. Specific removal of anti-Gal was performed by adsorption on fixed rabbit red cells.
Results:
Blood group O patients who underwent transplantation with either A or B kidney produced an antibody that bound to all three carbohydrate antigens. This multispecific antibody, designated anti-Gal A/B, is specific to the core alpha-gal epitope within A and B antigens. Recipients of allograft expressing incompatible blood group B also produce anti-Gal B antibody, which binds to the core alpha-gal epitope only in the B antigen. Anti-Gal A/B and anti-Gal B constitute most of the elicited anti-blood group antibody response. Allograft recipients also produced pure anti-A, or pure anti-B, which require the complete blood group structure for binding.
Conclusions:
The findings in this study imply that much of the immune response elicited by incompatible A or B antigens on kidney allografts results in activation of anti-Gal B-cell clones producing antibodies to the core alpha-gal epitope in these blood group antigens. Only less than 25% of the elicited antibodies interact with the complete A or B antigens (i.e., pure anti-A or pure anti-B). These findings suggest that prevention of the anti-Gal response may decrease the immune rejection of ABO-incompatible allografts.

Chemicals Related in the Paper:

Catalog Number	Product Name	Price
IAR42412412	Anti-ACIN1 antibody produced in rabbit	Price
IAR42413708	Anti-VEGFD antibody produced in rabbit	Price
IAR42413964	Anti-MYH3 antibody produced in rabbit	Price
IAR42414104	Anti-α-N-Catenin antibody produced in rabbit	Price
IAR42417005	Anti-phospho-OSR1 (pThr185) antibody produced in rabbit	Price
IAR4245890	Anti-FOXC2 antibody produced in rabbit	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: